The seroprevalence, waning rate, and protective duration of anti-diphtheria toxoid IgG antibody in Nha Trang, Vietnam

Noriko Kitamura, Lien Thuy Le, Thao Thi Thu Le, Hien-Anh Thi Nguyen, Tansy Edwards, Lina Madaniyazi, Minh Xuan Bui, Hung Thai Do, Duc-Anh Dang, Michiko Toizumi, Paul Fine, Lay-Myint Yoshida

PII: S1201-9712(22)00026-1
DOI: https://doi.org/10.1016/j.ijid.2022.01.025
Reference: IJID 5947

To appear in: International Journal of Infectious Diseases

Received date: 23 December 2021
Revised date: 11 January 2022
Accepted date: 12 January 2022

Please cite this article as: Noriko Kitamura, Lien Thuy Le, Thao Thi Thu Le, Hien-Anh Thi Nguyen, Tansy Edwards, Lina Madaniyazi, Minh Xuan Bui, Hung Thai Do, Duc-Anh Dang, Michiko Toizumi, Paul Fine, Lay-Myint Yoshida, The seroprevalence, waning rate, and protective duration of anti-diphtheria toxoid IgG antibody in Nha Trang, Vietnam, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.01.025

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Title:
The seroprevalence, waning rate, and protective duration of anti-diphtheria toxoid IgG antibody in Nha Trang, Vietnam

Authors:
Noriko Kitamura 1 2 3
Lien Thuy Le 4
Thao Thi Thu Le 4
Hien-Anh Thi Nguyen 5
Tansy Edwards 1 2
Lina Madaniyazi 2 3
Minh Xuan Bui 6
Hung Thai Do 4
Duc-Anh Dang 5
Michiko Toizumi 2 3
Paul Fine 1
Lay-Myint Yoshida 2 3 7
Affiliations:

1 Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK

2 School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan

3 Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

4 Department of Microbiology and Immunology, Pasteur Institute in Nha Trang, Nha Trang, Vietnam

5 National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

6 Khanh Hoa Provincial Health Services, Nha Trang, Vietnam

7 Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

Correspondence at refereeing and publication to:

Noriko Kitamura
Department of Infectious Disease Epidemiology,
London School of Hygiene and Tropical Medicine,
Keppel Street, London, WC1E 7HT, UK
Tel: +44, 7453521185
Email: Noriko.kitamura@lshtm.ac.uk

Post-publication Corresponding Author:

Lay-Myint Yoshida

Department of Pediatric Infectious Diseases,
Institute of Tropical Medicine, Nagasaki University, Japan
1-12-4, Sakamoto, Nagasaki
852-8523, JAPAN
Phone: +81 (0)95-819-7284
Fax: +81 (0)95-819-7843
Email: lmyoshi@nagasaki-u.ac.jp

Highlights

• The seroprevalence pattern by age is consistent with the age of the recent cases.
• The risk of diphtheria remains high in Vietnam, given the low seroprevalence.
- The vaccine immunity was estimated to be protective for 5 years after the 4th DTP.

- A school-entry booster dose (5-7 years) is recommended in Vietnam.

**Abstract:**

Background: Diphtheria cases reported in Central Vietnam since 2013 were mainly children aged 6-15 years, which may reflect an immunity gap. There is little information on diphtheria population immunity in countries without a school-entry booster dose. We aimed to measure the age-stratified seroprevalence of anti-diphtheria toxoid antibodies, quantify the change in antibodies in individuals over time, and estimate the length of protective immunity after vaccination in well-vaccinated communities in Vietnam.

Methods: An age-stratified seroprevalence survey among individuals aged 0-55 years was conducted at Nha Trang, Vietnam. The same participants were followed up after two years to quantify the change in antibodies. IgG was measured by ELISA. The length of protective immunity after vaccination was estimated using a mixed-effect linear regression model with random intercept.

Results: Overall seroprevalence was 26%(95%CI:20-32%). Age-stratified seroprevalence was 68%(95%CI:4-11%), 7%(95%CI:4-11%),
12%(95%CI:7-19%), 33%(95%CI:27-40%), and 28%(95%CI:17-43%) among those aged ≤5, 6-15, 16-25, 26-35, and 36-55 years, respectively. The antibody levels declined by 47%(95%CI:31-59%) over two years, and the predicted duration of vaccine-derived protective immunity was 4.3 years(95%CI:3.5–5.3) among participants aged six or younger after receiving four doses.

Conclusion: Given the low seroprevalence and short period of vaccine protection, a school-entry booster dose (5-7 years) is recommended in Vietnam.

Keywords: diphtheria, vaccine, schedule, immunity, DTP, Vietnam

Background:

Diphtheria is an acute infectious disease typically affecting the upper respiratory tract, which is mainly caused by toxin-producing Corynebacterium diphtheriae. Diphtheria used to be a major cause of child mortality, but introducing a highly effective toxoid vaccine decreased the disease burden. Recently, large-scale outbreaks were observed in Venezuela, Yemen, and the Rohingya population in Bangladesh, where the routine infant vaccination program was disrupted. Diphtheria remains endemic in many parts of the world. The number of cases increased in particular in South and Southeast Asia in the latter half of the 2010s compared with the earlier half. (WHO 2017, Clarke et al. 2019)
Currently, WHO recommends that a three-dose primary series of diphtheria toxoid-containing vaccine should be provided in early infancy, a first booster dose in the second year of life, and a second and a third booster at the age of school entry and school leaving. (WHO 2017) Nevertheless, many low-income countries have not introduced any booster dose yet. There is little information on the waning and the duration of immunity among children who receive three or four doses.

In Vietnam, the diphtheria-tetanus-pertussis (DTP) vaccine was introduced in 1981 and was replaced by the Pentavalent vaccine (DTP-Hib-HepB) in 2011. (MOH Vietnam 2012) The primary dose series was given at 2-3-4 months, and in 2012 a booster dose at 18 months was introduced. (MOH Vietnam 2012) Although the number of reported cases decreased sharply from 3500 per year in 1983 to nearly zero in 2010 (Jit et al. 2015), several outbreaks have been observed since 2013.

The 76 confirmed diphtheria cases in the Central and Highland region of Vietnam between 2014 and 2019 were aged between 1 and 55 years old, with 66% of the cases being children aged between 6-15 years (data in the Pasteur Institute in Nha Trang and the Institute of Hygiene and Epidemiology of Tay
Nguyen, Vietnam). The age distribution of diphtheria cases reflects the pattern of population immunity and thus the history of DTP schedule and coverage. (Galazka and Keja 1988, Galazka and Robertson 1995, Zakrzewska et al. 1997, Clarke et al. 2019) The population immunity will change over time since vaccine introduction. (Galazka 2000) In addition, it is known that the age of diphtheria cases typically shifts to older ages after the vaccine introduction. (Galazka and Keja 1988) This raises the question of how population immunity against diphtheria is currently in Vietnam. This study aimed to measure the age-stratified seroprevalence and geometric mean concentration (GMC) of anti-diphtheria toxoid antibodies in a study population in Nha Trang city, Vietnam, where high vaccination coverage was reported in most of the last ten years. The study also quantified the change of anti-diphtheria toxoid antibodies as a function of age, baseline IgG level, and number of DTP doses to investigate the antibody waning pattern. Finally, the study estimated the length of time that protective immunity above 0.1IU/ml was maintained after vaccination.
Materials and methods:

Study population and area

Nha Trang city, the capital of Khanh Hoa Province in Central Vietnam, has a population of over 300,000. (Yoshida et al. 2014) The two study communes, Vinh Hai and Vinh Phuoc communes, are adjacent to each other in the urban area of Nha Trang. According to a census conducted in 2015, the population size of the two communes was 42,397. Each commune has one health center which provides essential health services, including vaccination.

Study design and sampling method

A cohort study was conducted between 2017 and 2019. The sample population was originally selected for a cross-sectional seroprevalence survey of antibodies against dengue in June 2017. (Biggs et al. 2020) The original target sample size was 500, and the participants were over-recruited, considering potential non-respondents. Finally, a total of 510 samples were collected in 2017. Age-stratified simple random sampling was conducted in each commune based on census data. The five age strata were 0-5 years, 6-15 years, 16-25 years, 26-35 years, and 36-55 years in 2017, and samples of 50 were drawn randomly from each age stratum of the population data of each of the two communes.
These data were available for the current study, and all participants in the first cross-sectional survey were invited to join a follow-up survey in May 2019.

Study teams visited participants at their homes. Written informed consent was obtained from each participant or guardian if the participant was younger than 16 years old. The survey teams interviewed each participant using a standardized questionnaire collecting information on sex, date of birth, and oral vaccination history. In addition, venous blood samples were collected from participants at the commune health centers. Ethical approval was obtained from the Vietnamese Ministry of Health and the London School of Hygiene and Tropical Medicine ethical review boards (IRB-VN01057-27/2015, LSHTM Ethics ref: 17518/17913).

**Vaccination record in individuals and vaccination coverage**

We obtained written vaccination records from each individual’s vaccination card, in addition to the oral information, during the survey in 2019. If the vaccination card was not available, we searched the vaccination registration book, which recorded individual-based data at the local commune health center. We also collected administrative coverage data from the Department of Preventive Medicine in Nha Trang on the completed three-primary dose series of DTP (DTP3) and the fourth dose (DTP4) between 2011 to 2017 in the two study
local administrative coverage data before 2011 were not accessible. Thus we collected national administrative coverage data between 1983 and 2017 in Vietnam, obtained from the WHO data repository. (WHO 2021)

**Serological assay**

Collected sera were stored at -80°C in the Pasteur Institute in Nha Trang until testing. Serum anti-diphtheria toxoid IgG level was measured by a commercially available ELISA kit (IBL, Germany) following the manufacturer’s protocol. An IgG level above 0.1IU/ml in ELISA, the international standard cut-off value for the requirement of a booster dose, was considered seropositive. (European Center for Disease Prevention and Control 2014, von Hunolstein. C et al. 2014) The seroprevalence was defined as the proportion of seropositive samples amongst a total number of samples. We excluded samples that had errors in sample processing or testing.

**Statistical Analyses**

**Age-stratified seroprevalence and geometric mean concentration (GMC)**

Age-stratified seroprevalence and GMC were summarized with 95% confidence intervals using the cross-sectional survey data collected in 2017. To do this,
seroprevalence and GMC were weighted by population size in the ten age-sex strata in each commune. The sampling weights were the inverse probability of sampling in that age-sex stratum. The difference in weighted seroprevalence and weighted GMC between the sexes was examined by logistic regression and linear regression, respectively, by overall age and each age stratum. As an initial inspection of data revealed a large difference in immunity between two younger age groups, the seroprevalence and GMC were calculated by each year of age.

*Change in anti-diphtheria toxoid IgG antibody levels*

The change in anti-diphtheria toxoid IgG level was examined in participants who participated in both the 2017 (IgG1) and 2019 (IgG2) surveys. Due to the introduction of the fourth dose of DTP in the national immunisation programme in 2012, many participants who were born after 2011, aged six or younger in 2017, have received four doses following this change. On the other hand, participants aged seven years or older in 2017 have received three doses or less. In addition, observation of plotted IgG values showed that the IgG level declined most when participants were aged six or younger, while it often increased if participants were older than ten. We, therefore, stratified age by three groups at 0-6, 7-10, 11-55 years old for our analysis. We also categorized IgG1 into four groups, >0.1,
Change of IgG level over two years was evaluated using a change of natural log-transform IgG values (log(IgG2) – log(IgG1)). IgG levels were logarithmically transformed in statistical analyses to reduce the skewness of the data. Back-transformation of log-transformed changes gives ratios of geometric means. We, therefore, defined the percentage decrease of IgG as (1 - geometric mean of (IgG2/IgG1)) x 100 percent.

The percentage decrease in geometric mean levels over two years was reported for overall and exposure age groups 0-6, 7-10, and 11-55 years, and for IgG1 levels >0.1, 0.05-0.1, 0.03-0.05, and ≤0.03 IU/ml. The percentage decrease in geometric mean levels among age group 0-6 years was reported according to whether three or four DTP doses were received prior to the measurement of IgG1. The number of doses received that were confirmed on written vaccination records was used for stratification. The paired t-test was conducted to examine whether the change of natural log-transformed IgG in each group was statistically significant.
Duration of vaccine-derived protective immunity

The duration of vaccine-derived protective immunity was defined as the time since the last vaccination that IgG level was maintained above 0.1IU/ml. All available paired log-transformed IgG values (log(IgG1) and log(IgG2)) for children aged six or younger in 2017, who were born after 2011, with a history of three or four doses of DTP prior to measurement of IgG1 were included in the analysis. Their vaccination histories were confirmed on written vaccination records. We assumed that the immunity of children aged six or younger was attributable to vaccination.

A mixed-effect linear regression model with random intercept incorporating the between-individual variability was used to analyze antibody decay over time for anti-diphtheria toxoid IgG, whose decay pattern was assumed exponential, as reported in previously published studies. (Laird and Ware 1982, Renard et al. 2001, Bates et al. 2015, Hammarlund et al. 2016, Antia et al. 2018) The time at which the geometric mean level IgG is declined to 0.1U/ml was estimated from the line of best fit. This predicted time can be considered to correspond to the duration of protective immunity. A 95% confidence interval around this duration of protective immunity was calculated by the Delta method. (Oehlert 1992, Rice 2013)
Analyses were conducted in the STATA 15 software. (StataCorp 2017) R software was used for data visualization. (R Core Team (2020))

Results:

A total of 510 participants aged 0-55 years were recruited into the survey in 2017; 221 participants (43%) were male. A total of 306 participants (61%) were followed up in 2019. A written vaccination record was found for 108 participants aged 0-28 years. Ninety-four percent of the 0-5 years old participants had written vaccination records, and 71% had received four doses. The vaccination records of 60% of 6-15 years old participants were confirmed, and 54% had received three doses. (Table 1)

Vaccination coverage of DTP3 among participants who were born between 2007 and 2017 (aged 0-10 in 2017) in each year varied between 78 and 100% based on oral information and 33 to 100% based on vaccination records. The local and national administrative DTP3 coverage in the same period was between 92 and 100%, except 54% for the year 2013 when the Pentavalent vaccine was suspended in Vietnam during the investigation of one severe adverse event. (WHO 2021)
510 samples collected in 2017 were included to measure seroprevalence for the five age strata. Overall weighted seroprevalence was 26% (95% CI: 20%-32%). In this population, the highest seroprevalence was 68% (95% CI: 67%-69%) in age 0-5 years, and the lowest was 7% (95% CI: 4%-11%) in age 6-15 years. Seroprevalence levels in ages 16-25, 26-35, 36-55 years were 12% (95% CI: 7%-19%), 33% (95% CI: 27%-40%), and 28% (95% CI: 17%-43%), respectively. There was no statistical difference by sex in overall and age-stratified seroprevalence. (Table 2)

Seroprevalence constantly decreased from 85% in one-year-old to 0% in nine-year-old. It stayed at 0% until the age of twelve and gradually increased afterward. (Figure 1A). The highest GMC was 0.75 IU/ml at one year of age, and it declined to the lowest GMC 0.02 IU/ml at ten years of age. The decreasing and increasing trend of GMC over age was similar to that of seroprevalence. (Figure 1B)

Among 306 samples collected during the follow-up survey in 2019, and two samples had errors in sample processing or testing. Therefore, 304 paired samples were available to examine the change in IgG level between 2017 and 2019. Of 304 participants, 50 had a record of three doses, and 49 had received
four doses. None of these individuals received DTP or was diagnosed with diphtheria between 2017 and 2019.

All paired IgG values were plotted by age and number of DTP doses. (Figure 2A) The IgG levels declined rapidly in two years among children aged six or younger. While no consistent pattern of IgG change was observed in children aged seven or older, there was a particular pattern of IgG changes by IgG1 level. (Figure 2B) The percentage decrease of IgG in two years was calculated in different age groups by number of DTP doses and IgG1 levels. The percentage decrease of IgG was 41\% (95\%CI:28\%,52\%) over two years among those aged six or younger. IgG levels did not decline significantly among those who were older than six. The percentage decrease constantly diminished in accordance with the decline in IgG1 level. Among those who were aged under seven, the percentage decreases of IgG after receiving three or four doses of DTP were 34\% (95\%CI:-8\%,59\%) and 47\% (95\%CI:30\%,59\%), respectively. (Figure 2B and Table 3)

The length of time that the geometric mean of IgG was maintained above 0.1U/ml was estimated by a mixed-effect linear regression with a random intercept model. The number of samples included in the analysis was 114 (57
individuals) overall, 22 (11 individuals) of whom received three doses only, and 92 (46 individuals) of whom received four doses. IgG was estimated to be maintained above 0.1IU/ml for 4.7 years (95%CI:3.67-5.63) when the analysis was conducted combining those who received three or four doses. (Figure 3) IgG was estimated to be maintained above 0.1IU/ml for 4.3 years (95%CI:3.46-5.26) after receiving four doses. Due to the limited number of participants who received only three doses, we could not estimate the duration of protective immunity among them accurately.

Discussion:

This study describes the age-stratified seroprevalence from infants to adults in well-vaccinated communities where no school-entry booster dose has been introduced. The study demonstrates that 30 years of an immunisation programme, which provided three or four doses of DTP vaccines within the first two years of life, created a large immunity gap in the study population. Although the reported coverage was high, the seroprevalence was generally low among those aged 6-55 years. The age group in which the reported cases most frequently fell (6-15 years) and the broad age range of cases (1-55 years) in the last few years in Vietnam were consistent with observed seroprevalence pattern
by age. The rapid waning of immunity against diphtheria after vaccination may explain an increase in diphtheria cases in Vietnam and other countries in the late 2010s. (Wanlapakorn et al. 2014, Hughes et al. 2015, Sein et al. 2016, Sangal et al. 2017, WHO 2017)

Seroprevalence declined quickly from one to nine years of age. This result is different from a report showing that, after three doses of DTP in Germany, antibodies did not wane for the first ten years. (Hasselhorn et al. 1998) On the other hand, the pattern of declining seroprevalence in Sweden is similar to that which we observed in Vietnam. (Edmunds et al. 2000) The difference between populations may be due to the different vaccine components, schedule, and coverage, or the degree of natural infection, but none of them explain the difference clearly. Seroprevalence and GMC tended to increase after ten years of age, which suggests either ongoing transmission of toxigenic _C.diphtheriae_ or residual immunity from the transmission in the past.

The seroprevalence among children younger than five years was reported to be 64% in Lao PDR in 2012, which was similar to ours. (Nanthavong et al. 2015)

The seroprevalence between 15-24 years was 43% in another study in Lao in 2013, and that between 6-25 years was 32-52% in Kon Tum province in Vietnam.
in 2016. (Black et al. 2015, Le et al. 2017) The seroprevalence among aged 6-15 and 16-25 years in Lao and Kon Tum was higher than our results, which might have reflected natural infection of toxigenic *C. diphtheriae* as both study areas reported cases during the study period.

Although Nha Trang has had no reported diphtheria cases for at least the last ten years, seroprevalence among 0-55 years was as low as 26% (95%CI:20-32%). The absence of cases in Nha Trang may be attributable to the high DTP3 coverage among infants. Diphtheria cases have been reported where the infant DTP3 coverage was low, e.g., 23% in Rohingya refugee camps in 2017 (Rahman and Islam 2019) and 43% in Nigeria in 2011. (Besa et al. 2014) High immunity among young children may protect the community from large outbreaks even though the immunity among older children and adults is low.

There are several other potential explanations for the absence of cases despite the low seroprevalence. Our result might not accurately measure the protection level in individuals as we did not use a neutralization assay, a gold-standard assay. Cellular immunity may persist after vaccination and protect individuals, although antibodies are not detected. (Gunatillake and Taylor 1968, Heyworth and Ropp 1973)
According to historical data in North America prior to the vaccine introduction, clinical diphtheria was more common in boys among children and in women among adults. (Crum 1917) After vaccination was introduced, women were likely to have lower antibody levels than men. (Edmunds et al. 2000, Galazka 2000, Plotkin et al. 2018) Biological differences, the social role of women, or frequent opportunities of vaccination for men due to military services were discussed. But no clear reasons were identified. This study examined the sex difference in seroprevalence but found no significant difference.

This study shows no evidence of any difference in the waning rate of immunity between receiving three doses or four doses of DTP, though this may be due to the small sample size. The antibody level waned quickly among individuals with high antibody levels and increased among individuals with low antibody levels. This finding suggests that vaccine-derived immunity against diphtheria toxoid is not maintained for life. After it has waned, immunity may increase with subsequent subclinical or clinical infection, as previously reported. (Burnet 1972)

On the other hand, regression to the mean could also explain that a high antibody level is likely to decline and a low level of antibody likely to increase. (Barnett et al. 2004)
In this study, IgG was estimated to be maintained above 0.1IU/ml for 4.3 (95%CI:3.5-5.3) years after four doses of vaccine. Given that the fourth dose is currently scheduled at 18 months of age, 95% of children lose protection between ages of 5.0 and 6.8 years, and thus a booster dose should be administered at school entry which is at age six in Vietnam. As DTP was replaced in Vietnam by Pentavalent in 2011 and a booster dose at 18 months was introduced in 2012, most of the participants in this analysis had received vaccines according to the current vaccination programme. Therefore, the recommendation drawn from this study results will be suitable for Vietnam. This is also compatible with the current WHO recommendation.

This study has several strengths. We used written records to confirm the participants’ last vaccination date, which provided accurate vaccination history and time since the last vaccination in each individual. We used paired sera collected in the longitudinal study to estimate the waning of immunity over time.

There are several limitations to this study. It was conducted with a small sample size in a limited geographical area. We collected data only at two points in a fixed interval. The follow-up duration was short, and the results might be affected by random error as there were only two data points. The vaccination history
could not be confirmed among older participants, and thus the long-term effect of vaccine-derived immunity could not be evaluated.

An exponential decay model was used to estimate the length of time of vaccine protection up to seven years of age in this study. On the other hand, a previous study used a power function decay model to analyze the waning of anti-diphtheria toxoid IgG. (Swart et al. 2016) Another longitudinal study following up the same individuals for seven years showed a biphasic waning pattern of anti-diphtheria toxoid IgG. (Nakayama et al. 2019) The exponential decay model may not best fit, especially when follow-up time is longer.

**Conclusions:**

This study showed that the population aged six or older was largely susceptible in the study community in Vietnam, where the DTP3 coverage was high in the last ten years except in 2013. If any cases were imported or DTP3 coverage declined for some reason, there is a potential risk of re-emergence of the disease. Considering these risks, a cost-effectiveness analysis for introducing an additional booster dose may be warranted. The high case fatality ratio of diphtheria would justify a booster dose at school entry to reduce preventable
deaths. The study also showed that a school-entry booster dose would be required to maintain immunity against diphtheria in Vietnam.

**Acknowledgment:**

We would like to acknowledge Mr. The Tran Minh, the late former head of the Department of Bacteriology in the Pasteur Institute in Nha Trang, for his contribution to this research as well as all the participants and the survey teams in Khanh Hoa Province Health Services and health centers.

**Funding:**

This research was partially funded by the Nagasaki University WISE Program (Nagasaki University “Doctoral Program for World-leading Innovative and Smart Education” for Global Health, KENKYU SHIDO KEIHI “the Research Grant”), and Japan Program for Infectious Diseases Research and Infrastructure, Japan Agency for Medical Research and Development (AMED) [Grant Number: JP21wm0125006]

Funding sources had not been involved in study design, collection, analysis, and interpretation of data.

**Conflict of Interest:**

There is no conflict of interest to be declared.
**Ethical consideration:**

Ethical approval was obtained from the Vietnamese Ministry of Health and the London School of Hygiene and Tropical Medicine ethical review boards (IRB-VN01057-27/2015, LSHTM Ethics ref: 17518/17913)

**References:**


European Center for Disease Prevention and Control 2014. Evaluation and
assessment of serological immunity methods and EQA scheme of diphtheria.

Stockholm, ECDC.


against diphtheria, tetanus, pertussis, and poliovirus types I, II, and III following immunization with DTaP combined with inactivated wild-type polio vaccine (DTaP-wiPV). Japanese Journal of Infectious Diseases 72(1): 49-52.


StataCorp 2017 Stata Statistical Software: Release 15. College Station, TX, StataCorp LLC.


WHO 2017. Diphtheria vaccine: WHO position paper, August 2017 -

WHO. 2021. Immunization, Vaccines and Biologicals, Data, statistics and
graphics. from
https://apps.who.int/immunization_monitoring/globalsummary/countries?country
criteria%5Bcountry%5D%5B%5D=VNM. (accessed 23 November 2021)

Population based cohort study for pediatric infectious diseases research in

immunity to diphtheria in Poland in the past 40 years. Euro Surveill 2(8): 64-7.
Figure 1. A. Seroprevalence with 95% CI and nationwide DTP3 coverage by single age strata. The low DTP3 coverage in those aged four and 15 reflects the nationwide suspension of Pentavalent vaccines in 2013 and the stock out of DTP vaccines in 2017.

B. GMC with 95% CI. Dotted horizontal line represents the cut-off for protective immunity (0.1IU/ml)
Figure 2. Change of antibody (IgG) levels in 304 paired sera between 2017 and 2019 plotted over age by different number of DTP doses (A) and plotted by four categories of baseline IgG levels with boxplot showing median and first and third quantile of IgG in 2017 and IgG in 2019 (B)
Figure 3. Predicted geometric mean of IgG since the last vaccination after three or four doses of DTP with 95% confidence interval

Black line and gray area: Geometric mean of IgG concentration since the last vaccination and 95% confidence interval estimated by a mixed effect random intercept model.

Green squares and purple triangles: IgG concentration of each individual who received three doses and four doses of DTP, respectively.

The dotted line shows the protective threshold 0.1IU/ml. After three or four doses of DTP were given, predicted log-transformed anti-diphtheria toxoid IgG declined linearly and crossed 0.1IU/ml at 4.7 years after the last vaccination.
Table 1. The number of study participants by age group in 2017 and follow-up rate and vaccination history by participants’ age group in 2019.

Over 90% of the 0-5 years old participants’ vaccine record were available; 71% received four doses. Sixty percent of 6-15 years old have vaccine records, and 54% had a record of received three doses.

<table>
<thead>
<tr>
<th>Year of Birth</th>
<th>Number of Participants</th>
<th>Follow-up Rate (2017)</th>
<th>Number of Vaccines Received (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012 0-5 yr</td>
<td>1</td>
<td>20 (3)</td>
<td>number of vaccines received (4, 3, 2, 1, 0)</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>21 (5)</td>
<td>4% 3% 2% 1% 0%</td>
</tr>
<tr>
<td>2002 6-15 yr</td>
<td>1</td>
<td>21 (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>21 (5)</td>
<td></td>
</tr>
<tr>
<td>1992 16-25 yr</td>
<td>1</td>
<td>21 (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>21 (5)</td>
<td></td>
</tr>
<tr>
<td>1982 26-35 yr</td>
<td>1</td>
<td>21 (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>21 (5)</td>
<td></td>
</tr>
<tr>
<td>1962 36-55 yr</td>
<td>1</td>
<td>21 (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>21 (5)</td>
<td></td>
</tr>
</tbody>
</table>

Ninety-four percent of the 0-5 year old participants had a written vaccination record; 71% received four doses. 60% of 6-15 year old have vaccine records, and 54% had a record of three doses. The very different vaccine history of DTP3 and DTP4 in the youngest two age groups occurred because the national vaccination programme introduced the fourth dose in 2012. Participants aged over 36 years in 2017 were not vaccinated because DTP was not
introduced in Vietnam until 1981.

Table 2. Seroprevalence (seropositive was defined as IgG value above 0.1IU/ml) and the geometric mean concentration (GMC) weighted by population size, age and sex structures in two communes in Nha Trang city in 2017.

<table>
<thead>
<tr>
<th>All</th>
<th>Seroprevalence p-value (Male vs Female)</th>
<th>GMC p-value (Male vs Female)</th>
</tr>
</thead>
<tbody>
<tr>
<td>age group</td>
<td>mean age, ±SD(year)</td>
<td>N</td>
</tr>
<tr>
<td>0-5yr</td>
<td>3.8 ±0.02</td>
<td>100</td>
</tr>
<tr>
<td>6-15yr</td>
<td>11.1 ±2.74</td>
<td>107</td>
</tr>
<tr>
<td>16-25yr</td>
<td>20.2 ±5.92</td>
<td>105</td>
</tr>
<tr>
<td>26-35yr</td>
<td>31.1 ±1.19</td>
<td>94</td>
</tr>
<tr>
<td>36-55yr</td>
<td>45.7 ±2.44</td>
<td>104</td>
</tr>
<tr>
<td>total</td>
<td>28.9 ±3.01</td>
<td>510</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-5yr</td>
<td>3.8 ±0.37</td>
<td>50</td>
</tr>
<tr>
<td>6-15yr</td>
<td>11.1 ±5.5</td>
<td>60</td>
</tr>
<tr>
<td>16-25yr</td>
<td>20 ±1.97</td>
<td>46</td>
</tr>
<tr>
<td>26-35yr</td>
<td>30.8 ±0.46</td>
<td>30</td>
</tr>
<tr>
<td>36-55yr</td>
<td>45.1 ±4.88</td>
<td>35</td>
</tr>
<tr>
<td>total</td>
<td>28.2 ±4.76</td>
<td>221</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-5yr</td>
<td>3.9 ±0.45</td>
<td>50</td>
</tr>
<tr>
<td>6-15yr</td>
<td>11.1 ±1.73</td>
<td>47</td>
</tr>
<tr>
<td>16-25yr</td>
<td>20.4 ±6.57</td>
<td>59</td>
</tr>
<tr>
<td>26-35yr</td>
<td>31.4 ±1.45</td>
<td>64</td>
</tr>
<tr>
<td>36-55yr</td>
<td>46.2 ±2.71</td>
<td>69</td>
</tr>
<tr>
<td>total</td>
<td>29.7 ±2.34</td>
<td>289</td>
</tr>
</tbody>
</table>

Sex difference in seroprevalence was compared by logistic regression, sex difference in GMC was compared by linear regression.
Table 3. The percent reduction of IgG among four baseline IgG levels, five age groups, and number of doses of DTP.

<table>
<thead>
<tr>
<th>N</th>
<th>% decrease</th>
<th>95%CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>all paired samples</td>
<td>304</td>
<td>16%</td>
<td>(8%,24%)</td>
</tr>
<tr>
<td>age groups</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-6 years</td>
<td>66</td>
<td>41%</td>
<td>(28%,52%)</td>
</tr>
<tr>
<td>7-10 years</td>
<td>27</td>
<td>-18%</td>
<td>(-40%,1%)</td>
</tr>
<tr>
<td>11-55 years</td>
<td>211</td>
<td>11%</td>
<td>(0%,20%)</td>
</tr>
<tr>
<td>baseline IgG level in 2017</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;0.1IU/ml</td>
<td>90</td>
<td>56%</td>
<td>(48%,63%)</td>
</tr>
<tr>
<td>0.05-0.1IU/ml</td>
<td>73</td>
<td>15%</td>
<td>(5%,24%)</td>
</tr>
<tr>
<td>0.03-0.05IU/ml</td>
<td>61</td>
<td>2%</td>
<td>(-12%,15%)</td>
</tr>
<tr>
<td>&lt;=0.03IU/ml</td>
<td>80</td>
<td>-50%</td>
<td>(-77%,-28%)</td>
</tr>
<tr>
<td>age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 or 4 doses</td>
<td>57</td>
<td>44%</td>
<td>(30%,55%)</td>
</tr>
<tr>
<td>0-6 years</td>
<td>3 doses</td>
<td>11</td>
<td>34%</td>
</tr>
<tr>
<td>only</td>
<td>4 doses</td>
<td>46</td>
<td>47%</td>
</tr>
</tbody>
</table>

Percentage decrease = (1- geometric mean of (IgG2/IgG1) *100 percent
IgG1: IgG measured in 2017, IgG2: IgG measured in 2019